129 related articles for article (PubMed ID: 36743234)
1. Double Pretransplant Positivity for Autoantibodies to LG3 and Angiotensin II Type 1 Receptor Is Associated With Alloimmune Vascular Injury in Kidney Transplant Recipients.
Carroll R; Turgeon J; Deayton S; Emery T; Bilogrevic F; Jahan S; Rimbaud AK; Georges B; Tavares-Brum A; Hébert MJ; Cardinal H
Transplant Direct; 2023 Feb; 9(2):e1437. PubMed ID: 36743234
[TBL] [Abstract][Full Text] [Related]
2. Anti-LG3 Antibodies Aggravate Renal Ischemia-Reperfusion Injury and Long-Term Renal Allograft Dysfunction.
Yang B; Dieudé M; Hamelin K; Hénault-Rondeau M; Patey N; Turgeon J; Lan S; Pomerleau L; Quesnel M; Peng J; Tremblay J; Shi Y; Chan JS; Hébert MJ; Cardinal H
Am J Transplant; 2016 Dec; 16(12):3416-3429. PubMed ID: 27172087
[TBL] [Abstract][Full Text] [Related]
3. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
Cardinal H; Dieudé M; Brassard N; Qi S; Patey N; Soulez M; Beillevaire D; Echeverry F; Daniel C; Durocher Y; Madore F; Hébert MJ
Am J Transplant; 2013 Apr; 13(4):861-874. PubMed ID: 23432943
[TBL] [Abstract][Full Text] [Related]
4. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant positivity for circulating thyroid antibodies and graft survival in patients undergoing kidney transplant.
Rotondi M; Leporati P; Lodigiani S; Netti GS; Precerutti S; Magri F; Rosati A; Pradella F; Salvadori M; Serio M; Romagnani P; Chiovato L
Horm Res; 2009; 71(6):324-30. PubMed ID: 19506389
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to LG3 are associated with poor long-term survival after liver retransplantation.
Xu Q; McAlister VC; House AA; Molinari M; Leckie S; Zeevi A
Clin Transplant; 2021 Jul; 35(7):e14318. PubMed ID: 33871888
[TBL] [Abstract][Full Text] [Related]
7. Proactive treatment of angiotensin receptor antibodies in kidney transplantation with plasma exchange and/or candesartan is safe and associated with excellent graft survival at 4 years: A single centre Australian experience.
Carroll RP; Deayton S; Emery T; Munasinghe W; Tsiopelas E; Fleet A; Lake M; Humphreys I; Jalalonmuhali M; Coates P
Hum Immunol; 2019 Aug; 80(8):573-578. PubMed ID: 31014826
[TBL] [Abstract][Full Text] [Related]
8. Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol.
Yazawa M; Cseprekal O; Helmick RA; Talwar M; Balaraman V; Podila PSB; Agbim UA; Maliakkal B; Fossey S; Satapathy SK; Sumida K; Kovesdy CP; Nair S; Eason JD; Molnar MZ
Nephron; 2020; 144(3):126-137. PubMed ID: 32007998
[TBL] [Abstract][Full Text] [Related]
9. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection.
Soulez M; Pilon EA; Dieudé M; Cardinal H; Brassard N; Qi S; Wu SJ; Durocher Y; Madore F; Perreault C; Hébert MJ
Circ Res; 2012 Jan; 110(1):94-104. PubMed ID: 22076637
[TBL] [Abstract][Full Text] [Related]
10. New insights into immune mechanisms of antiperlecan/LG3 antibody production: Importance of T cells and innate B1 cells.
Padet L; Dieudé M; Karakeussian-Rimbaud A; Yang B; Turgeon J; Cailhier JF; Cardinal H; Hébert MJ
Am J Transplant; 2019 Mar; 19(3):699-712. PubMed ID: 30129231
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
12. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.
Deltombe C; Gillaizeau F; Anglicheau D; Morelon E; Trébern-Launay K; Le Borgne F; Rimbert M; Guérif P; Malard-Castagnet S; Foucher Y; Giral M
Transpl Int; 2017 Nov; 30(11):1150-1160. PubMed ID: 28686316
[TBL] [Abstract][Full Text] [Related]
13. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
14. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
[TBL] [Abstract][Full Text] [Related]
15. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
[TBL] [Abstract][Full Text] [Related]
16. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
[TBL] [Abstract][Full Text] [Related]
17. Human pregnancy and generation of anti-angiotensin receptor and anti-perlecan antibodies.
Hönger G; Cardinal H; Dieudé M; Buser A; Hösli I; Dragun D; Hébert MJ; Schaub S
Transpl Int; 2014 May; 27(5):467-74. PubMed ID: 24661626
[TBL] [Abstract][Full Text] [Related]
18. Pretransplant angiotensin II type 1-receptor antibodies point to an increase in renal graft sub-intimal fibrosis in living- donor kidney transplant recipients.
González-Almada A; Arreola-Guerra JM; López-Sánchez JA; Cuevas E; Vilatoba M; Contreras AG; Morales-Buenrostro LE; Alberu J; Uribe-Uribe NO
Transpl Immunol; 2019 Jun; 54():1-8. PubMed ID: 30336216
[TBL] [Abstract][Full Text] [Related]
19. Pre-Transplant Angiotensin II Type 1 Receptor Antibodies and Anti-Endothelial Cell Antibodies Predict Graft Function and Allograft Rejection in a Low-Risk Kidney Transplantation Setting.
Yu S; Huh HJ; Lee KW; Park JB; Kim SJ; Huh W; Jang HR; Kwon GY; Moon HH; Kang ES
Ann Lab Med; 2020 Sep; 40(5):398-408. PubMed ID: 32311853
[TBL] [Abstract][Full Text] [Related]
20. Pretransplant Renal Arterial Vasculopathy of Donor Predicts Poor Renal Allograft Survival.
Özdemir BH; Özdemir FN; Börcek P; Sercan Ç; Özdemir G; Ayvazoğlu Soy EH; Haberal M
Exp Clin Transplant; 2018 Mar; 16 Suppl 1(Suppl 1):41-46. PubMed ID: 29527990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
